Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PBH shares.
View PBH analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month price objectives for Prestige Consumer Healthcare's shares. Their PBH share price targets range from $103.00 to $117.00. On average, they expect the company's stock price to reach $110.00 in the next twelve months. This suggests a possible upside of 60.7% from the stock's current price.
View analysts price targets for PBH or view top-rated stocks among Wall Street analysts.

Prestige Consumer Healthcare's stock was trading at $61.22 at the start of the year. Since then, PBH stock has increased by 11.8% and is now trading at $68.46.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PBH earnings forecast.

Prestige Consumer Healthcare Inc. (NYSE:PBH) released its quarterly earnings results on Thursday, February, 8th. The company reported $1.06 earnings per share for the quarter, topping analysts' consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million for the quarter, compared to the consensus estimate of $280.25 million. Prestige Consumer Healthcare had a positive trailing twelve-month return on equity of 14.09% and a negative net margin of 7.11%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.04 EPS.

ETFs with the largest weight of Prestige Consumer Healthcare (NYSE:PBH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Schwab Ariel ESG ETF (SAEF), Global X Health & Wellness ETF (BFIT), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and iShares U.S. Pharmaceuticals ETF (IHE).

Prestige Consumer Healthcare issued an update on its FY 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of 4.330-4.330 for the period, compared to the consensus estimate of 4.320. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

8 employees have rated Prestige Consumer Healthcare Chief Executive Officer Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among the company's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (2.11%), Congress Asset Management Co. MA (1.54%) and Congress Wealth Management LLC DE (0.25%). Insiders that own company stock include Mary Beth Fritz and Ronald M Lombardi.
View institutional ownership trends.

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.